Comparative trials on the effects of two fungicides on a predatory mite in the laboratory and in the field

2000 ◽  
Vol 97 (3) ◽  
pp. 321-330 ◽  
Author(s):  
S. Blümel ◽  
C. Pertl ◽  
F.M. Bakker
Keyword(s):  
Predatory Mite ◽  
Comparative Trials

What habitat does spiny snout mite occupy in Tasmania

2015 ◽  
Vol 68 ◽  
pp. 446-446
Author(s):  
D.J. Wilson ◽  
P.J. Gerard
Keyword(s):  
New Zealand ◽  
Sand Dune ◽  
Biocontrol Agent ◽  
Predatory Mites ◽  
Mite Species ◽  
Predatory Mite ◽  
Habitat Specificity ◽  
Nontarget Organisms ◽  
Flea Control ◽  
Potential Biocontrol Agent

Spiny snout mite (Neomolgus capillatus) is a potential biocontrol agent for clover flea (Sminthurus viridis) a white clover pest on dairy farms in warmer and wetter parts of New Zealand In the 1990s this mite was introduced from Brittany France into Tasmania for clover flea control Results during the release programme were highly promising and subsequent anecdotal farmer reports indicate widespread decreases in damage As N capillatus is a predatory mite and already known to attack nontarget organisms habitat specificity will determine whether it could be introduced into New Zealand without risk to native insects To assess this pastures on nine of the original Tasmanian release farms and adjacent nontarget habitats ranging from bush wetlands eucalypt stands to sand dune country were sampled in April 2014 Litter samples were collected heat extracted and mite species identified Neomolgus capillatus was found at effective densities in pastures that had good clover cover Where present it displaced Bdellodes spp mites that are ineffective against clover flea No N capillatus were found in the nontarget habitats all of which lacked clover and contained other predatory mites including Bdellodes spp Therefore the preference by N capillatus for lush pastures makes it an excellent prospect for introduction as a biocontrol agent into clover flea prone regions of New Zealand

Comparative trials of the test-plates for calculation of QMA&OAMO in poultry products

2019 ◽  
Vol 21 (4) ◽  
pp. 52-55
Author(s):  
S.S. Kozak ◽  
◽  
N.L. Dogadova ◽  
Yu.A. Kozak ◽  
R.T. Abdraimov ◽  
...  
Keyword(s):  
Poultry Products ◽  
Comparative Trials

Is Treat-to-target in Lupus Nephritis Realistic in Clinical Practice?

2018 ◽  
Vol 15 (1) ◽  
pp. 2-6 ◽  
Author(s):  
Chi Chiu Mok
Keyword(s):  
Lupus Nephritis ◽  
Disease Activity ◽  
Safety Concern ◽  
Real Life ◽  
Current Treatment ◽  
Treat To Target ◽  
Low Disease Activity ◽  
Activity State ◽  
Definition Of ◽  
Comparative Trials

The Treat-to-Target (T2T) principle has been advocated in a number of inflammatory and non-inflammatory medical illnesses. Tight control of disease activity has been shown to improve the outcome of rheumatoid arthritis and psoriatic arthritis as compared to the conventional approach. However, whether T2T can be applied to patients with lupus nephritis is still under emerging discussion. Treatment of lupus nephritis should target at inducing and maintaining remission of the kidney inflammation so as to preserve renal function and improve survival in the longterm. However, there is no universal agreement on the definition of remission or low disease activity state of nephritis, as well as the time points for switching of therapies. Moreover, despite the availability of objective parameters for monitoring such as proteinuria and urinary sediments, differentiation between ongoing activity and damage in some patients with persistent urinary abnormalities remains difficult without a renal biopsy. A large number of serum and urinary biomarkers have been tested in lupus nephritis but none of them have been validated for routine clinical use. In real life practice, therapeutic options for lupus nephritis are limited. As patients with lupus nephritis are more prone to infective complications, tight disease control with aggressive immunosuppressive therapies may have safety concern. Not until the feasibility, efficacy, safety and cost-effectiveness of T2T in lupus nephritis is confirmed by comparative trials, this approach should not be routinely recommended with the current treatment armamentarium and monitoring regimes.

scholarly journals Mint companion plants attract the predatory mite Phytoseiulus persimilis

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Kazuki Togashi ◽  
Mifumi Goto ◽  
Hojun Rim ◽  
Sayaka Hattori ◽  
Rika Ozawa ◽  
...  
Keyword(s):  
Phytoseiulus Persimilis ◽  
Predatory Mite ◽  
Companion Plants

scholarly journals Pregnancy and neonatal outcomes in fresh and frozen cycles using blastocysts derived from ovarian stimulation with follitropin delta

2021 ◽  
Author(s):  
Jon Havelock ◽  
Anna-Karina Aaris Henningsen ◽  
Bernadette Mannaerts ◽  
Joan-Carles Arce ◽  
Keyword(s):  
Ovarian Stimulation ◽  
Implantation Rate ◽  
Neonatal Outcomes ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Relative Contribution ◽  
Follitropin Alfa ◽  
Start Up ◽  
Comparative Trials

Abstract Purpose To describe the pregnancy and neonatal outcomes using fresh and vitrified/warmed blastocysts obtained from ovarian stimulation with follitropin delta in controlled trials versus follitropin alfa. Methods This investigation evaluated the outcome from 2719 fresh and frozen cycles performed in 1326 IVF/ICSI patients who could start up to three ovarian stimulations in the ESTHER-1 (NCT01956110) and ESTHER-2 (NCT01956123) trials, covering 1012 fresh cycles and 341 frozen cycles with follitropin delta and 1015 fresh cycles and 351 frozen cycles with follitropin alfa. Of the 1326 first cycle patients, 513 continued to cycle 2 and 188 to cycle 3, and 441 patients started frozen cycles after the fresh cycles. Pregnancy follow-up was continued until 4 weeks after birth. Results The overall cumulative take-home baby rate after up to three stimulation cycles was 60.3% with follitropin delta and 60.7% with follitropin alfa (−0.2% [95% CI: −5.4%; 5.0%]), of which the relative contribution was 72.8% from fresh cycles and 27.2% from frozen cycles in each treatment group. Across the fresh cycles, the ongoing implantation rate was 32.1% for follitropin delta and 32.1% for follitropin alfa, while it was 27.6% and 27.8%, respectively, for the frozen cycles. Major congenital anomalies among the live-born neonates up until 4 weeks were reported at an incidence of 1.6% with follitropin delta and 1.8% with follitropin alfa (−0.2% [95% CI: −1.9%; 1.5%]). Conclusions Based on comparative trials, the pregnancy and neonatal outcomes from fresh and frozen cycles provide reassuring data on the efficacy and safety of follitropin delta. Trial registration ClinicalTrials.gov Identifier: NCT01956110 registered on 8 October 2013; NCT01956123 registered on 8 October 2013.

Sign in / Sign up

Export Citation Format

Share Document